Eli Lilly and Company $LLY Stock Acquired by Composition Wealth LLC

Composition Wealth LLC boosted its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 4.0% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 23,868 shares of the company’s stock after acquiring an additional 909 shares during the period. Composition Wealth LLC’s holdings in Eli Lilly and Company were worth $27,617,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Chancellor Financial Group WB LP increased its position in shares of Eli Lilly and Company by 1.3% in the third quarter. Chancellor Financial Group WB LP now owns 930 shares of the company’s stock valued at $1,076,000 after acquiring an additional 12 shares during the period. TD Capital Management LLC raised its stake in shares of Eli Lilly and Company by 10.6% during the third quarter. TD Capital Management LLC now owns 73 shares of the company’s stock valued at $85,000 after acquiring an additional 7 shares during the last quarter. Stelac Advisory Services LLC purchased a new stake in shares of Eli Lilly and Company during the third quarter worth about $16,259,000. Bogart Wealth LLC boosted its holdings in shares of Eli Lilly and Company by 26.4% during the third quarter. Bogart Wealth LLC now owns 16,345 shares of the company’s stock worth $18,913,000 after purchasing an additional 3,409 shares during the period. Finally, Global Retirement Partners LLC boosted its holdings in shares of Eli Lilly and Company by 2.7% during the third quarter. Global Retirement Partners LLC now owns 31,369 shares of the company’s stock worth $36,296,000 after purchasing an additional 833 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 1.3%

NYSE:LLY opened at $1,412.63 on Wednesday. The company has a 50-day moving average price of $1,253.71 and a 200-day moving average price of $1,114.28. The stock has a market cap of $1.33 trillion, a price-to-earnings ratio of 45.85, a P/E/G ratio of 1.71 and a beta of 0.40. The company has a current ratio of 1.39, a quick ratio of 1.00 and a debt-to-equity ratio of 1.17. Eli Lilly and Company has a 12 month low of $850.51 and a 12 month high of $1,475.25.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The company had revenue of $24.40 billion for the quarter, compared to analysts’ expectations of $22.58 billion. During the same quarter in the previous year, the company earned $7.02 earnings per share. Eli Lilly and Company’s quarterly revenue was up 38.6% on a year-over-year basis. Equities analysts predict that Eli Lilly and Company will post 35.70 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th. Eli Lilly and Company’s payout ratio is presently 22.46%.

Insiders Place Their Bets

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the transaction, the executive vice president owned 4,137 shares in the company, valued at approximately $5,802,225.24. This represents a 54.72% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.14% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on LLY. Berenberg Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating and set a $1,400.00 target price on the stock in a research note on Tuesday, September 15th. Sanford C. Bernstein reaffirmed an “outperform” rating and set a $1,450.00 price target on shares of Eli Lilly and Company in a research report on Monday, October 26th. Argus lifted their price objective on Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the stock a “buy” rating in a research report on Friday, October 30th. Jefferies Financial Group lifted their price objective on Eli Lilly and Company from $1,610.00 to $1,700.00 and gave the stock a “buy” rating in a research report on Monday, November 9th. Finally, China Merchants Securities cut Eli Lilly and Company from a “buy” rating to a “hold” rating in a research note on Thursday, November 12th. One analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $1,422.00.

View Our Latest Report on LLY

Trending Headlines about Eli Lilly and Company

These are some of the LLY headlines that stood out recently:

Eli Lilly and Company Profile

(Free Report)

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Featured Articles

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.